Elevance Health, Inc.
ELV
$399.18
-1.33%
Elevance Health, Inc. is a leading health insurer in the United States, providing medical benefits to approximately 45 million members through employer, individual, and government-sponsored plans. The company is distinguished as the largest single provider of Blue Cross Blue Shield branded coverage, operating as a licensee in 14 states, and has expanded its reach in government programs like Medicaid and Medicare Advantage through strategic acquisitions. The current investor narrative is heavily focused on the regulatory environment for Medicare Advantage payments, with recent news of a larger-than-expected 2027 payment increase from the Centers for Medicare & Medicaid Services (CMS) boosting sector-wide sentiment and revenue visibility for Elevance and its peers.…
ELV
Elevance Health, Inc.
$399.18
Investment Opinion: Should I buy ELV Today?
Rating & Thesis: Hold. ELV presents a balanced risk/reward profile where positive regulatory catalysts and attractive valuation are offset by significant quarterly earnings volatility and technical overextension. The bullish analyst consensus and recent momentum are acknowledged, but the core investment thesis requires confirmation of sustained margin recovery.
Supporting Evidence: The stock trades at a compelling 13.73x trailing P/E, a discount to its historical range and in line with industry peers. It generates strong free cash flow ($3.17B TTM, 4.1% yield) and offers a 1.97% dividend. However, Q4 net margin collapsed to 1.10% from 4.47% in Q1, and revenue growth decelerated to 9.47% YoY. The 41% three-month rally has pushed the price to 99.4% of its 52-week high, limiting near-term upside absent new catalysts.
Risks & Conditions: The two biggest risks are 1) a failure to stabilize quarterly profitability, and 2) a technical reversal from overbought conditions. This Hold rating would upgrade to a Buy if the forward P/E (14.00x) compresses further on sustained earnings growth or if Q1 2026 results demonstrate a clear rebound in net margins above 3%. It would downgrade to Sell if revenue growth decelerates below 8% or if the stock breaks below key support at $350. The stock is currently fairly valued relative to its near-term growth prospects and risk profile.
Sign up to view all
ELV 12-Month Price Forecast
The outlook is bifurcated between a powerful fundamental recovery story and a cautionary tale of earnings volatility. The base case is most likely, expecting consolidation after a sharp rally, with the stock's fate hinging on the next few quarterly reports. The bullish CMS catalyst is already largely priced in at current levels. A shift to a bullish stance would require concrete evidence of margin recovery in the upcoming Q1 2026 earnings. Conversely, another weak quarter would likely validate the bear case and trigger a significant de-rating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $518.93 and implied upside of +30.0% versus the current price.
Average Target
$518.93
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$319 - $519
Analyst target range
Analyst coverage for Elevance Health is robust, with six analysts providing estimates. The consensus sentiment is bullish, as evidenced by the institutional ratings which show recent actions from major firms like Mizuho, JP Morgan, Wells Fargo, and Barclays all maintaining 'Overweight' or 'Buy' equivalents. The average target price is derived from consensus revenue and EPS estimates; the estimated EPS average is $46.51 on estimated revenue of $237.41 billion. While a specific consensus price target is not provided in the data, the bullish ratings and upward sector momentum following the CMS news imply positive analyst sentiment and likely upside to the current price. The range of analyst estimates shows a degree of uncertainty but general optimism. The estimated EPS high is $48.65, while the low is $45.03, representing a relatively tight spread of about 8%. Similarly, the revenue estimate range is from $231.62 billion to $245.81 billion. The high-end estimates likely incorporate more bullish assumptions about membership growth, margin expansion from the improved Medicare payment environment, and successful execution in the Carelon services segment. The low-end estimates may reflect concerns about regulatory headwinds or medical cost inflation. The recent series of reaffirmed 'Buy' and 'Overweight' ratings in January and February 2026, following the stock's downturn and subsequent recovery, indicates analysts see fundamental strength and value at current levels.
Bulls vs Bears: ELV Investment Factors
The bull case, currently supported by stronger evidence, hinges on a powerful valuation re-rating catalyzed by improved regulatory clarity and robust technical momentum. The bear case centers on alarming quarterly earnings volatility and questions about the sustainability of the recent parabolic move. The single most important tension in the investment debate is whether the positive sentiment shift from the CMS payment news can overcome the fundamental weakness evidenced by the severe Q4 2025 net income compression. The resolution of this tension—specifically, whether upcoming quarters show margin stabilization—will determine if this is a durable recovery or a temporary relief rally.
Bullish
- Strong Medicare Advantage Payment Boost: The recent CMS announcement of a larger-than-expected 2027 Medicare Advantage payment increase provides significant revenue visibility and has catalyzed a sector-wide rally. This directly addresses a key regulatory overhang and supports future earnings growth for Elevance's government-sponsored plans.
- Compelling Valuation at Historical Lows: The stock trades at a trailing P/E of 13.73x, near the bottom of its historical range, which has been as high as 50.19x. This valuation is in line with or at a discount to the managed care industry average, offering a margin of safety if fundamentals improve.
- Powerful Technical Reversal & Momentum: The stock has surged 41.36% over the past three months, recovering from a -34.69% drawdown. It now trades at 99.4% of its 52-week high ($411.80), with a 1-month relative strength of +6.34 points against the S&P 500, indicating strong buying pressure and a decisive sentiment shift.
- Robust Free Cash Flow Generation: The company generates substantial free cash flow, with TTM FCF of $3.17 billion, yielding approximately 4.1% relative to its market cap. This funds a stable dividend (1.97% yield) and share repurchases, providing shareholder returns and financial flexibility.
Bearish
- Severe Quarterly Profitability Volatility: Q4 2025 net income collapsed to $547 million (1.10% net margin) from $2.18 billion (4.47% margin) in Q1 2025. This extreme volatility in quarterly earnings, driven by medical cost pressures, creates significant uncertainty for investors.
- Revenue Growth Deceleration: Q4 2025 revenue growth decelerated to 9.47% YoY, down from 14.8% in Q1 2025. This sequential slowdown, if persistent, could challenge the narrative of durable top-line expansion and limit multiple expansion potential.
- Technical Overextension Near Resistance: The stock trades just below its 52-week high of $411.80 after a parabolic 46% rally from March lows. This leaves little room for error and increases vulnerability to a pullback or consolidation if it fails to break decisively above this key resistance level.
- Chronic Underperformance vs. Market: Despite the recent surge, ELV's 1-year return of 7.73% significantly underperformed the S&P 500's 27.04% gain, resulting in a negative 1-year relative strength of -19.31 points. This long-term weakness suggests deeper structural concerns that may resurface.
ELV Technical Analysis
The stock is in a strong recovery trend, having gained 41.36% over the past three months, which sharply contrasts with its modest 7.73% one-year gain. As of the latest close at $409.44, the price is trading near the top of its 52-week range, approximately 99.4% of the way towards its 52-week high of $411.80, indicating significant momentum but also potential overextension. Recent momentum is exceptionally strong, with the stock up 10.94% over the past month, significantly outperforming the S&P 500's 4.6% gain, as evidenced by a positive 1-month relative strength of 6.34 points. This short-term acceleration diverges from the stock's underperformance over the past year, where it posted a negative relative strength of -19.31 points against the market, suggesting a powerful reversal from previous weakness. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $411.80 and support at the 52-week low of $273.71. A decisive breakout above resistance would confirm the strength of the current uptrend, while a failure could lead to a consolidation near these highs. The stock exhibits a beta of 0.67, indicating it is approximately 33% less volatile than the broader market (SPY), which is notable given its recent sharp price movements and suggests the stock may offer a relatively defensive profile within the healthcare sector despite its recent surge. The price action shows the stock experienced a significant drawdown of -34.69% from its peak, bottoming around $280 in early March 2026, before embarking on its current powerful rally. The recovery has been supported by above-average volume, with a recent daily average of 1.42 million shares, and a high short ratio of 3.34 suggests a degree of bearish positioning that may have contributed to the sharp upside move through short covering. The stock's ability to rally over 46% from its March lows to current levels demonstrates robust buying pressure and a shift in market sentiment.
Beta
0.68
0.68x market volatility
Max Drawdown
-34.2%
Largest decline past year
52-Week Range
$274-$427
Price range past year
Annual Return
+4.8%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +1.5% | -0.1% |
| 3m | +36.9% | +11.4% |
| 6m | +11.2% | +8.2% |
| 1y | +4.8% | +22.7% |
| ytd | +12.7% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Revenue growth has been solid but showed some sequential deceleration in the most recent quarter. For Q4 2025, revenue was $49.75 billion, representing a year-over-year growth rate of 9.47%. However, this marks a slowdown from the stronger growth rates seen in prior quarters of 2025, such as Q1's 14.8% YoY growth (from $42.58B to $48.89B). The business is segmented, with the Health Benefits segment generating $41.84 billion and the Carelon Services segment contributing $18.66 billion, indicating the core insurance operations drive the majority of top-line results. Profitability metrics have been volatile on a quarterly basis, with net income for Q4 2025 at $547 million, resulting in a net margin of 1.10%. This represents a significant compression from the Q1 2025 net income of $2.18 billion and a net margin of 4.47%. The gross margin for Q4 2025 was 23.48%, which is below the trailing twelve-month gross margin of 25.56% indicated in the valuation data, suggesting some quarterly pressure on medical cost ratios. The company remains profitable on an annual basis, but the quarterly volatility, particularly the sharp drop in Q4 net income, warrants close monitoring of cost trends and medical loss ratios. The balance sheet and cash flow position appear healthy. The company maintains a conservative debt profile with a debt-to-equity ratio of 0.76 and a solid current ratio of 1.24. Return on equity (ROE) is a respectable 12.90%. Trailing twelve-month free cash flow is strong at $3.17 billion, providing ample internal funding for dividends (payout ratio of 27.0%, yield of 1.97%) and share repurchases. The free cash flow yield, based on the current market cap of approximately $77.75 billion, is around 4.1%, indicating the company generates meaningful cash relative to its valuation.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.23%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Given the company's consistent profitability with positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 13.73x, while the forward P/E is slightly higher at 14.00x based on estimated EPS of $46.51. The minimal gap between trailing and forward multiples suggests the market is pricing in relatively stable, modest earnings growth expectations for the coming year. Compared to typical industry averages for managed care companies (which often trade in the mid-to-high teens P/E range), Elevance's P/E multiple of ~14x appears to be at a discount or in line, rather than at a premium. The stock also trades at a Price-to-Sales (P/S) ratio of 0.39x and an EV/Sales of 0.40x, which are very low multiples that reflect the thin net margins characteristic of the health insurance industry but may also indicate the market assigns a lower growth multiple to the business model. Historically, the stock's own valuation has compressed significantly. The current trailing P/E of 13.73x is near the bottom of its historical range observed in the provided data, which shows P/E ratios as high as 50.19x in Q4 2024 and typically ranging between 11x and 35x over the past several years. Trading near the low end of its own historical band suggests the market may be pricing in a more pessimistic outlook or that the stock offers relative value if fundamentals stabilize or improve, especially following the recent positive Medicare Advantage news.
PE
13.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is extreme quarterly earnings volatility, as demonstrated by the plunge in Q4 2025 net income to $547 million (1.1% margin) from over $2 billion in prior quarters. This indicates potential vulnerability to medical cost inflation and pricing pressures. While the balance sheet is solid with a 0.76 debt-to-equity ratio, the sharp margin compression raises concerns about the company's ability to consistently translate its $237 billion revenue base into stable profits. Revenue growth deceleration to 9.47% YoY in Q4 adds to the operational uncertainty.
Market & Competitive Risks: The stock's valuation, while historically low, remains sensitive to sector-wide regulatory headlines and competitive dynamics in government-sponsored plans. The recent 41% surge in three months, outperforming the market by 28.76 points, has pushed the stock to the top of its 52-week range, creating valuation compression risk if growth expectations are not met. Despite a low beta of 0.67 suggesting defensive characteristics, the stock's high short ratio of 3.34 indicates persistent market skepticism that could lead to heightened volatility around earnings.
Worst-Case Scenario: The worst-case scenario involves a recurrence of severe medical cost inflation coinciding with a regulatory setback, triggering a return to the Q4 2025 margin profile and multiple compression. This could see the stock re-test its 52-week low of $273.71, representing a potential downside of approximately -33% from the current price of $409.44. A break below this level could occur if the company misses earnings estimates and guides lower, potentially leading to a drawdown approaching the -34.69% maximum observed during the recent downturn.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: Q4 2025 net margin collapsed to 1.10%, demonstrating high sensitivity to medical costs. 2) Regulatory Risk: Despite positive CMS news, the healthcare insurance sector remains perpetually exposed to government payment changes and policy shifts. 3) Technical Reversal Risk: The stock is overextended after a 41% 3-month rally, with a high short ratio of 3.34, increasing vulnerability to a pullback. 4) Growth Deceleration Risk: Q4 revenue growth slowed to 9.47% YoY, which could pressure the growth narrative.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $400 and $425, assuming earnings meet the $46.51 consensus and the P/E multiple holds around 14x. The Bull Case (30% probability) targets $430-$460, driven by successful margin expansion and multiple expansion. The Bear Case (20% probability) warns of a drop to $275-$320 if profitability weakens further. The base case is most likely, implying the recent rally may consolidate, with the stock's direction heavily dependent on the next few quarterly earnings reports confirming or denying a margin recovery.
ELV appears fairly valued to slightly undervalued on an absolute basis but rich on a technical basis. Its trailing P/E of 13.73x is near the bottom of its own historical range (previously as high as 50x) and in line with managed care peers, suggesting the market is not assigning a premium. The low P/S ratio of 0.39x reflects thin margins. However, after a 46% rally from its lows, the stock trades at 99.4% of its 52-week high, indicating limited near-term upside absent new positive earnings surprises. The valuation implies the market expects modest, stable growth but remains skeptical of a full earnings recovery.
ELV is a Hold, not a clear-cut buy at current levels. While its valuation at 13.73x P/E is attractive and the recent CMS news is positive, the stock has already rallied 41% in three months to trade near its 52-week high. The severe quarterly earnings volatility, with Q4 net income dropping to $547 million, introduces significant risk. It could be a good buy for patient, value-oriented investors on a pullback towards $380, provided they are comfortable with the sector's regulatory risks and the company's execution challenges in stabilizing margins.
ELV is more suitable for a long-term (2+ year) investment horizon than for short-term trading. Its low beta of 0.67 indicates lower volatility relative to the market, which is better for holding. The dividend (1.97% yield) and share repurchases funded by strong FCF reward patient shareholders. However, the extreme quarterly earnings volatility makes it a poor short-term trading vehicle, as single earnings reports can cause sharp moves. Investors should be prepared to hold through potential volatility to realize the value from its discounted valuation and await a full fundamental turnaround.